1-17 of 17
Laura Maria Fogliatto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib in Patients with Chronic Myeloid Leukemia Who Failed Two or More Tyrosine Kinase Inhibitors - Clinical Outcomes from a Managed Access Program in Brazil

Katia B Pagnano, Isabela Assis de Siqueira, Giulia de Campos, Natalia Cristina Rojas Guerrero, Johnny FC Camargo, Gislaine Oliveira Duarte, Guilherme Duffles, Victor H Guidini, Bruna Sabioni, Fernanda Salles Seguro, Nelson Hamerschlak, Morgani Rodrigues, Emanuella Graciott Souza, Patricia Santos Resende Cardoso, Gustavo HR Magalhães, Acy Telles De Souza Quixada, Adriana Seber, Ires Hamyra Bezerra Massaut, Laura Maria Fogliatto, Natalia Nunes Gonçalves, Rafael De Sá Vasconcelos, Simone Vidor, Carmino De Souza, Vaneuza Funke
Journal: Blood
Blood (2024) 144 (Supplement 1): 6603.
https://doi.org/10.1182/blood-2024-208360
Published: 2024
Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Martin Dreyling, Jiri Mayer, David Belada, Yuqin Song, Wojciech Jurczak, Jonas Paludo, Michael P. Chu, Iryna Kryachok, Laura Maria Fogliatto, Chan Y. Cheah, Marta Morawska, Juan-Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Michael Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1626.
https://doi.org/10.1182/blood-2024-200290
Published: 2024
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Leila Perobelli, Mihoko Yamamoto, Valeria Buccheri, Raphael Costa Bandeira de Melo, Sérgio Costa Fortier, Rodrigo Santucci, Marcelo Bellesso, Glaciano Ribeiro, Nelson Hamerschlak, Abel Costa Neto, Vera Figueiredo, Laura Maria Fogliatto, Sergio Augusto B Brasil, Marcelo Lacerda, Matheus Vescovi Goncalves, Carlos Chiattone, Celso Arrais-Rodrigues
Journal: Blood
Blood (2023) 142 (Supplement 1): 6534.
https://doi.org/10.1182/blood-2023-190590
Published: 2023
Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia A. Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, John C. Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G. Wierda, Veerendra Munugalavadla, Catherine Wangui Wachira, Chuan-Chuan Wun, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 636.
https://doi.org/10.1182/blood-2023-174750
Published: 2023
Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 3771–3772.
https://doi.org/10.1182/blood-2022-157710
Published: 2022
Journal Articles

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Marcelo Pitombeira de Lacerda, Fernanda de Morais Marques, Verena Pfister, Flavia de Carvalho Parra, Vinicius Campos de Molla, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Maria Fogliatto, Rodrigo Santucci, Marcelo Bellesso, Sérgio Costa Fortier, Talita M.B. Silveira, Glaciano Ribeiro, Nelson Hamerschlak, Mihoko Yamamoto, Matheus Vescovi Goncalves, Carlos S. Chiattone, Celso Arrais-Rodrigues
Journal: Blood
Blood (2022) 140 (Supplement 1): 7041–7042.
https://doi.org/10.1182/blood-2022-170872
Published: 2022
Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Jean-Jacques Kiladjian, David M Ross, Laura Maria Fogliatto, Lynda Foltz, Lambert Busque, Zhijian Xiao, Florian H. Heidel, Michael Koehler, Giuseppe A. Palumbo, Massimo Breccia, Norio Komatsu, Keita Kirito, Blanca Xicoy Cirici, Joaquin Martinez-Lopez, Alicia Rovo, Cheryl Petruk, Mike Zuurman, Laura Mirams, Abigail McMillan, Gavin Harper, Claire Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 12162–12164.
https://doi.org/10.1182/blood-2022-162516
Published: 2022
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-142565
Published: 2020
Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Wellington F Silva, MD, Valeria Buccheri, Alita Azevedo, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Laura Maria Fogliatto, MD PhD, Leila Martins Perobelli, MD, Glaciano Ribeiro, MD, Germison Silva Lopes, Vera Lucia de Piratininga Figueiredo, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-142520
Published: 2020
Journal Articles

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Laura Maria Fogliatto, MD PhD, Cristiana Solza, MD PhD, Alexandre Gustavo Apa, MD, Gustavo HR Magalhaes, MD MSc, Marcia Torresan Delamain, MD, Renato Tavares, MD, Lorena Lobo Figueiredo-Pontes, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5851.
https://doi.org/10.1182/blood-2019-121960
Published: 2019
Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5844.
https://doi.org/10.1182/blood-2019-127530
Published: 2019
Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William G. Wierda, MD PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 31.
https://doi.org/10.1182/blood-2019-128404
Published: 2019
Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, MD, Marek Trněný, Koji Izutsu, MDPhD, Nathan H. Fowler, MD, Xiaonan Hong, MD, Jun Zhu, Huilai Zhang, MDPhD, Fritz Offner, MD, Adriana Scheliga, MD, Grzegorz S. Nowakowski, MD, Antonio Pinto, MD, Francesca Re, MDPhD, Laura Maria Fogliatto, MD, Phillip Scheinberg, MD, Ian W. Flinn, MD PhD, Cláudia Moreira, MD, David Liu, MDPhD, Stacey Kalambakas, MD, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 445.
https://doi.org/10.1182/blood-2018-99-110861
Published: 2018
Journal Articles

DA-EPOCH Was Not Better Than CHOP for Acquired Immunodeficiency Syndrome-Related Diffuse Large B Cell Lymphoma Patients Treated in a South Brazilian University Hospital

Carolina F Gomes, MD, Tito Vanelli, MD, Gueverson Rocha, Biomedical, Jeziel Basso, MD, Juliana Collman Silva, MD, Nicole Teixeira Carvalho, MD, Tatiana de Campos, MD, Harold Fabian Ibanez Torres, MD, Lucia Silla, MD PhD, Paz Aparecida Alessandra, MD, Laura Maria Fogliatto, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5414.
https://doi.org/10.1182/blood-2018-99-117862
Published: 2018